Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of the third-line chemotherapy in patients with advanced pancreatic cancer.
Authors
Bomi Kim
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea;
Bomi Kim , Jinwoo Ahn , Jae Hyup Jung , Kwangrok Jung , Jong-Chan Lee , Jin-Hyeok Hwang , Jaihwan Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 711)
DOI
10.1200/JCO.2023.41.4_suppl.711
Abstract #
711
Poster Bd #
K18
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapy.
First Author: Thomas H. Cartwright
Poster
2013 ASCO Annual Meeting
Updated use of first-line chemotherapy for advanced pancreatic cancer: Folfirinox versus gemcitabine.
First Author: Thomas H. Cartwright
Poster
2021 ASCO Annual Meeting
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407).
First Author: Masato Ozaka
Poster
2018 ASCO Quality Care Symposium
Treatment patterns, toxicity, and outcomes of elderly patients with advanced pancreatic cancer receiving first-line chemotherapy.
First Author: Robert Kudlovich